Skip to main content
SpringerLink
Log in

Introduction to Lung Disease

  • Chapter
  • First Online:
Microbiome in Inflammatory Lung Diseases

  • 528 Accesses

Abstract

The global incidence of lung disease (LD) affecting children and adults is steadily increasing. The source of mortality and morbidity of lung diseases is unknown. However, current data from the WHO and other institutions show that there are approximately 400 million people worldwide suffering from mild to severe COPD and asthma. Lung diseases can be classified as non-infectious (asthma, chronic obstructive pulmonary disease (COPD), lung cancer, cystic fibrosis, and idiopathic pulmonary fibrosis (IPF)) or infectious (tuberculosis, influenza and COVID-19) disease and method transfer. Lung diseases have a huge impact on a global scale and are becoming more common due to the ageing population and the lack of appropriate interventions to minimise the risk factors that lead to the development of these diseases. Asthma, COPD, fibrosis, COVID-19, and influenza-like lung diseases have become life-threatening and life-threatening, effective treatments and appropriate preventive measures have become challenges for researchers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Alba MA, Flores-Suárez LF, Henderson AG, Xiao H, Hu P, Nachman PH et al (2017) Interstitial lung disease in ANCA vasculitis. Autoimmun Rev 16(7):722–729

    Article  PubMed  PubMed Central  Google Scholar 

  2. Albtoush OM, Al-Mnayyis A, Christopher K, Werner S, Jürgen H, Horger M (2018) [Differential diagnosis of cystic lung diseases]. Rofo 190(12):1103–1107

    Google Scholar 

  3. Ali MS, Ghori UK, Musani AI (2019) Orphan lung diseases. Med Clin North Am 103(3):503–515

    Article  PubMed  Google Scholar 

  4. Azadeh N, Moua T, Baqir M, Ryu JH (2018) Treatment of acute exacerbations of interstitial lung disease. Expert Rev Respir Med 12(4):309–313

    Article  CAS  PubMed  Google Scholar 

  5. Barba T, Mainbourg S, Nasser M, Lega JC, Cottin V (2019) Lung diseases in inflammatory myopathies. Semin Respir Crit Care Med 40(2):255–270

    Article  PubMed  Google Scholar 

  6. Bittmann I (2021) [Drug-induced interstitial lung diseases]. Pathologe 42(1):11–16

    Google Scholar 

  7. Boateng E, Krauss-Etschmann S (2020) miRNAs in lung development and diseases. Int J Mol Sci. 21(8):2765

    Article  CAS  PubMed Central  Google Scholar 

  8. Britto CJ, Brady V, Lee S, Dela Cruz CS (2017) Respiratory viral infections in chronic lung diseases. Clin Chest Med 38(1):87–96

    Article  PubMed  Google Scholar 

  9. Chen J, Jin Y, Yang Y, Wu Z, Wu G (2020) Epithelial dysfunction in lung diseases: effects of amino acids and potential mechanisms. Adv Exp Med Biol 1265:57–70

    Article  CAS  PubMed  Google Scholar 

  10. Cinetto F, Scarpa R, Rattazzi M, Agostini C (2018) The broad spectrum of lung diseases in primary antibody deficiencies. Eur Respir Rev. 27(149):180019

    Article  PubMed  Google Scholar 

  11. Collins BF, Raghu G (2019) Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. Eur Respir Rev. 28(153):190022

    Article  PubMed  Google Scholar 

  12. Cottin V (2016) Eosinophilic lung diseases. Clin Chest Med 37(3):535–556

    Article  PubMed  Google Scholar 

  13. Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M et al (2018) Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 27(150):180076

    Article  PubMed  Google Scholar 

  14. Cottin V, Valenzuela C (2020) Diagnostic approach of fibrosing interstitial lung diseases of unknown origin. Presse Med 49(2):104021

    Article  PubMed  Google Scholar 

  15. Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S (2019) Fibrosing interstitial lung diseases: knowns and unknowns. Eur Res Rev. 28(151):180100

    Article  Google Scholar 

  16. Dawod YT, Cook NE, Graham WB, Madhani-Lovely F, Thao C (2020) Smoking-associated interstitial lung disease: update and review. Expert Rev Respir Med 14(8):825–834

    Article  CAS  PubMed  Google Scholar 

  17. Fazen LE, Linde B, Redlich CA (2020) Occupational lung diseases in the 21st century: the changing landscape and future challenges. Curr Opin Pulm Med 26(2):142–148

    Article  PubMed  Google Scholar 

  18. Ferro F, Delle SA (2018) The use of ultrasound for assessing interstitial lung involvement in connective tissue diseases. Clin Exp Rheumatol 36 Suppl 114(5):165–170

    PubMed  Google Scholar 

  19. George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ et al (2020) Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med 8(9):925–934

    Article  PubMed  Google Scholar 

  20. Griese M (2018) Chronic interstitial lung disease in children. Eur Respir Rev. 27(147):170100

    Article  PubMed  Google Scholar 

  21. Gupta N, Ryu JH (2020) Controversies and evolving concepts in orphan lung diseases. Semin Respir Crit Care Med 41(2):175–176

    Article  PubMed  Google Scholar 

  22. Ha YJ, Lee YJ, Kang EH (2018) Lung involvements in rheumatic diseases: update on the epidemiology, pathogenesis, clinical features, and treatment. Biomed Res Int 2018:6930297

    Article  PubMed  PubMed Central  Google Scholar 

  23. Harris EJA, Musk A, de Klerk N, Reid A, Franklin P, Brims FJH (2019) Diagnosis of asbestos-related lung diseases. Expert Rev Respir Med 13(3):241–249

    Article  CAS  PubMed  Google Scholar 

  24. Hoy RF, Brims F (2017) Occupational lung diseases in Australia. Med J Aust 207(10):443–448

    Article  PubMed  Google Scholar 

  25. Jacobs K, Kligerman S (2019) Immune-Mediated Lung Diseases. Semin Ultrasound CT MR 40(3):213–228

    Article  PubMed  Google Scholar 

  26. Jiang J, Xiao K, Chen P (2017) NOTCH signaling in lung diseases. Exp Lung Res 43(4–5):217–228

    Article  CAS  PubMed  Google Scholar 

  27. Kanne JP (2019) Smoking-related diffuse lung diseases. Semin Roentgenol 54(1):30–36

    Article  PubMed  Google Scholar 

  28. Khateeb J, Fuchs E, Khamaisi M (2019) Diabetes and lung disease: a neglected relationship. Rev Diabet Stud 15:1–15

    Article  PubMed  PubMed Central  Google Scholar 

  29. Khoor A, Colby TV (2017) Amyloidosis of the lung. Arch Pathol Lab Med 141(2):247–254

    Article  PubMed  Google Scholar 

  30. Kolb M, Bondue B, Pesci A, Miyazaki Y, Song JW, Bhatt NY et al (2018) Acute exacerbations of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 27(150):180071

    Article  PubMed  Google Scholar 

  31. Kolb M, Vašáková M (2019) The natural history of progressive fibrosing interstitial lung diseases. Respir Res 20(1):57

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kumar A, Cherian SV, Vassallo R, Yi ES, Ryu JH (2018) Current concepts in pathogenesis, diagnosis, and management of smoking-related interstitial lung diseases. Chest 154(2):394–408

    Article  PubMed  Google Scholar 

  33. Kylhammar D, Rådegran G (2017) [Pulmonary hypertension due to lung diseases]. Lakartidningen 114:562–569

    Google Scholar 

  34. Lahousse L (2019) Epigenetic targets for lung diseases. EBioMedicine 43:24–25

    Article  PubMed  PubMed Central  Google Scholar 

  35. Latshang TD, Schoch OD (2017) [Lung diseases and altitude mountaineering]. Ther Umsch 74(10):555–562

    Google Scholar 

  36. Lenga Ma Bonda W, Iochmann S, Magnen M, Courty Y, Reverdiau P (2018) Kallikrein-related peptidases in lung diseases. Biol Chem 399(9):959–971

    Article  CAS  PubMed  Google Scholar 

  37. Liu PP, Yang SN, Dai HP, Wang C (2020) [The role of exosome in the lung diseases]. Zhonghua Jie He He Hu Xi Za Zhi 43(8):692–7

    Google Scholar 

  38. Liu Y, Gao H, Wang X, Zeng Y (2020) Methylation of inflammatory cells in lung diseases. Adv Exp Med Biol 1255:63–72

    Article  CAS  PubMed  Google Scholar 

  39. Maher TM, Wuyts W (2019) Management of fibrosing interstitial lung diseases. Adv Ther 36(7):1518–1531

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Margaritopoulos GA, Antoniou KM, Wells AU (2017) Comorbidities in interstitial lung diseases. Eur Respir Rev. 26(143):160027

    Article  PubMed  Google Scholar 

  41. Mira-Avendano I, Abril A, Burger CD, Dellaripa PF, Fischer A, Gotway MB et al (2019) Interstitial lung disease and other pulmonary manifestations in connective tissue diseases. Mayo Clin Proc 94(2):309–325

    Article  PubMed  Google Scholar 

  42. Montesi SB, Fisher JH, Martinez FJ, Selman M, Pardo A, Johannson KA (2020) Update in interstitial lung disease 2019. Am J Respir Crit Care Med 202(4):500–507

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Nathan N, Berdah L, Borensztajn K, Clement A (2018) Chronic interstitial lung diseases in children: diagnosis approaches. Expert Rev Respir Med 12(12):1051–1060

    Article  CAS  PubMed  Google Scholar 

  44. Nathan N, Berdah L, Delestrain C, Sileo C, Clement A (2020) Interstitial lung diseases in children. Presse Med. 49(2):103909

    Article  PubMed  Google Scholar 

  45. Nogee LM (2017) Interstitial lung disease in newborns. Semin Fetal Neonatal Med 22(4):227–233

    Article  PubMed  PubMed Central  Google Scholar 

  46. Olson AL, Gifford AH, Inase N, Fernández Pérez ER, Suda T (2018) The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur Respir Rev. 27(150):180077

    Article  PubMed  Google Scholar 

  47. Palla J, Sockrider MM (2019) Congenital lung malformations. Pediatr Ann 48(4):e169–ee74

    Article  PubMed  Google Scholar 

  48. Perelas A, Silver RM, Arrossi AV, Highland KB (2020) Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med 8(3):304–320

    Article  CAS  PubMed  Google Scholar 

  49. Perlman DM, Maier LA (2019) Occupational lung disease. Med Clin North Am 103(3):535–548

    Article  PubMed  Google Scholar 

  50. Ray A, Jaiswal A, Dutta J, Singh S, Mabalirajan U (2020) A looming role of mitochondrial calcium in dictating the lung epithelial integrity and pathophysiology of lung diseases. Mitochondrion 55:111–121

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Reinero C (2019) Interstitial lung diseases in dogs and cats part II: known cause and other discrete forms. Vet J. 243:55–64

    Article  PubMed  Google Scholar 

  52. Richeldi L, Varone F, Bergna M, de Andrade J, Falk J, Hallowell R et al (2018) Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev. 27(150):180074

    Article  PubMed  Google Scholar 

  53. Rivera-Ortega P, Molina-Molina M (2019) Interstitial lung diseases in developing countries. Ann Glob Health. 85(1):4

    Article  PubMed  PubMed Central  Google Scholar 

  54. Rout-Pitt N, Farrow N, Parsons D, Donnelley M (2018) Epithelial mesenchymal transition (EMT): a universal process in lung diseases with implications for cystic fibrosis pathophysiology. Respir Res 19(1):136

    Article  PubMed  PubMed Central  Google Scholar 

  55. Salinas M, Florenzano M, Wolff V, Rodríguez JC, Valenzuela H, Fernández C et al (2019) [Update on interstitial lung diseases]. Rev Med Chil 147(11):1458–1467

    Google Scholar 

  56. Aljabali AA, Bakshi HA, Satija S, Metha M, Prasher P, Ennab RM et al (2020) COVID-19: underpinning research for detection, therapeutics, and vaccines development. Pharm Nanotechnol 8(4):323–353

    Article  CAS  PubMed  Google Scholar 

  57. Anand K, Vadivalagan C, Joseph JS, Singh SK, Gulati M, Shahbaaz M et al (2021) A novel nano therapeutic using convalescent plasma derived exosomal (CPExo) for COVID-19: a combined hyperactive immune modulation and diagnostics. Chem Biol Interact 344:109497

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Khan T, Agnihotri K, Tripathi A, Mukherjee S, Agnihotri N, Gupta G (2020) COVID-19: a worldwide, zoonotic, pandemic outbreak. Altern Ther Health Med 26:56–64

    PubMed  Google Scholar 

  59. Mehta M, Prasher P, Sharma M, Shastri MD, Khurana N, Vyas M et al (2020) Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): a hypothesis. Med Hypotheses 144:110254

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Prasher P, Sharma M, Gupta G, Chellappan DK, Dua K (2020) Are medicinal plants an alternative strategy to combat COVID-19? Altern Ther Health Med 26:92–93

    PubMed  Google Scholar 

  61. Rawat S, Dhramshaktu IS, Pathak S, Singh SK, Singh H, Mishra A et al (2020) The impact of COVID-19 pandemic infection in patients admitted to the hospital for reasons other than COVID-19 infection. Altern Ther Health Med 26:108–111

    PubMed  Google Scholar 

  62. Satija S, Mehta M, Sharma M, Prasher P, Gupta G, Chellappan DK et al (2020) Vesicular drug delivery systems as theranostics in COVID-19. Newlands Press Ltd, London

    Book  Google Scholar 

  63. Shahcheraghi SH, Ayatollahi J, Aljabali AA, Shastri MD, Shukla SD, Chellappan DK et al (2021) An overview of vaccine development for COVID-19. Ther Deliv 12(3):235–244

    Article  CAS  PubMed  Google Scholar 

  64. Sharma M, Prasher P, Mehta M, Zacconi FC, Singh Y, Kapoor DN et al (2020) Probing 3CL protease: rationally designed chemical moieties for COVID-19. Drug Dev Res. https://doi.org/10.1002/ddr.21724

  65. Singh Y, Gupta G, Mishra A, Chellappan DK, Dua K (2020) Gender and age differences reveal risk patterns in COVID-19 outbreak. Altern Ther Health Med 26:54–55

    PubMed  Google Scholar 

  66. Sunkara K, Allam VR, Shukla SD, Chellappan DK, Gupta G, MacLoughlin R et al (2021) COVID-19 in underlying COPD patients. EXCLI J 20:248

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia

    Waleed Hassan Almalki

Authors
  1. Waleed Hassan Almalki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Waleed Hassan Almalki .

Editor information

Editors and Affiliations

  1. School of Pharmacy, Suresh Gyan Vihar University, Jaipur, India

    Gaurav Gupta

  2. School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia

    Brian G. Oliver

  3. Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia

    Kamal Dua

  4. School of Pharmacy, Suresh Gyan Vihar University, Jaipur, India

    Alisha Singh

  5. R&D Science and Emerging Technologies, Aerogen Limited, Dangan, Ireland

    Ronan MacLoughlin

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive licence to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Almalki, W.H. (2022). Introduction to Lung Disease. In: Gupta, G., Oliver, B.G., Dua, K., Singh, A., MacLoughlin, R. (eds) Microbiome in Inflammatory Lung Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-16-8957-4_1

Download citation

Publish with us

Policies and ethics

Search

Navigation